Eli Lilly & Co. (LLY-N) Stock Predictions - Stockchase
WATCH LIST
37
Eli Lilly & Co. (LLY-N)

ON STOCKCHASE SINCE Jun 2001

Insulin eqip mfctr

biotechnology/pharmaceutical

Eli Lilly & Co.

LLY-N

17 watching          
Join the Discussion

Eli Lilly & Co. (LLY-N) SAVE Apr, 19, 2019, 9:04 am

115.20 1.3 (1.12%)

About Eli Lilly & Co. (LLY-N)

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. More at Wikipedia

What the experts are saying about LLY-N



  • All
  • Filtered
Signal Opinion Expert
PAST TOP PICK
Eli Lilly & Co.(LLY-N) 

April 15, 2019

(A Top Pick Dec 18/18, Up 17%) He owned a lot in this sector and sold on strength. He would have no problem buying it if he did not have a healthcare stock. It is one of the few areas that are truly in a secular bull market.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
(A Top Pick Dec 18/18, Up 17%) He owned a lot in this sector and sold on strength. He would have no problem buying it if he did not have a healthcare stock. It is one of the few areas that are truly in a secular bull market.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$124.080
Owned Owned
No

HOLD
Eli Lilly & Co.(LLY-N) 

April 8, 2019

He is not yet taking profits. They dominate the insulin business. As the world gets larger and overeats … The stock takes patience. It will probably sell off with the market.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
He is not yet taking profits. They dominate the insulin business. As the world gets larger and overeats … The stock takes patience. It will probably sell off with the market.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$127.130
Owned Owned
Yes

WATCH
Eli Lilly & Co.(LLY-N) 

March 22, 2019

What does the increase in volume signal? Some technicians see volume as confirmation. You need volume spike to confirm a move. On the downside, volume doesn't tell you a lot, as things can start slowly. So don't read too much into it. If this stock comes back down to north of $105, a lot of investors would probably come back in. A good name, if you didn't want to buy XLD or HHL.T.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
What does the increase in volume signal? Some technicians see volume as confirmation. You need volume spike to confirm a move. On the downside, volume doesn't tell you a lot, as things can start slowly. So don't read too much into it. If this stock comes back down to north of $105, a lot of investors would probably come back in. A good name, if you didn't want to buy XLD or HHL.T.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$128.300
Owned Owned
Unknown

TOP PICK
Eli Lilly & Co.(LLY-N) 

December 18, 2018

Broke out over the summer. Healthcare is one of the few sectors that's in a secular bull market, and is even making new highs in the current bull market. LLY tends to beat guidance. They deliver. This trend should continue into 2019. (Analysts’ price target is $114.96)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Broke out over the summer. Healthcare is one of the few sectors that's in a secular bull market, and is even making new highs in the current bull market. LLY tends to beat guidance. They deliver. This trend should continue into 2019. (Analysts’ price target is $114.96)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Hap (Robert) Sn

Chief Port, Castlemoore Inc....

Price Price
$106.500
Owned Owned
Yes

TOP PICK
Eli Lilly & Co.(LLY-N) 

October 18, 2018

Just bought it. They have come with new pills for diabetes with huge potential. Yield of 2.0%. Drugs stocks are in favor. Likes the sector.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Just bought it. They have come with new pills for diabetes with huge potential. Yield of 2.0%. Drugs stocks are in favor. Likes the sector.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Bruce Murray

CEO & Chie, The Murray Wealth Gr...

Price Price
$113.310
Owned Owned
Yes

HOLD
Eli Lilly & Co.(LLY-N) 

May 10, 2017

He likes this. They have a diversified pipeline. Had a couple of mishaps. A fair amount was baked into their Alzheimer’s drug in November, and they kind of walked away from it. Also, their anti-inflammatory did not get FDA approval. There was some positive data from their Monarch pretrial, phase 3 of breast cancer. This is a very strong hold.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

He likes this. They have a diversified pipeline. Had a couple of mishaps. A fair amount was baked into their Alzheimer’s drug in November, and they kind of walked away from it. Also, their anti-inflammatory did not get FDA approval. There was some positive data from their Monarch pretrial, phase 3 of breast cancer. This is a very strong hold.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$81.050
Owned Owned
Yes

DON'T BUY
Eli Lilly & Co.(LLY-N) 

November 24, 2016

The whole drug sector in general has been suffering badly. For the last decade or so, it has been almost impossible to raise drug prices. The election of Donald Trump may be favourable to the drug sector. They are all suffering with the increasing movement of generic drugs, and all have relatively weak pipelines. Most of the pharma sector is struggling, and even cutting back on research and development. He would look elsewhere.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

The whole drug sector in general has been suffering badly. For the last decade or so, it has been almost impossible to raise drug prices. The election of Donald Trump may be favourable to the drug sector. They are all suffering with the increasing movement of generic drugs, and all have relatively weak pipelines. Most of the pharma sector is struggling, and even cutting back on research and development. He would look elsewhere.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Lorne Steinberg

President , Lorne Steinberg Weal...

Price Price
$68.000
Owned Owned
Unknown

DON'T BUY
Eli Lilly & Co.(LLY-N) 

April 13, 2016

Right now Pharma is struggling. This company has cash generation and a diversified portfolio lineup. There are a number of factors for right now, but healthcare is facing a lot of headwinds now. You should be looking at this in the 10s, maybe low teens growth profile.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Right now Pharma is struggling. This company has cash generation and a diversified portfolio lineup. There are a number of factors for right now, but healthcare is facing a lot of headwinds now. You should be looking at this in the 10s, maybe low teens growth profile.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Cameron Hurst

Chief Inve, Equium Capital Manag...

Price Price
$75.160
Owned Owned
No

DON'T BUY
Eli Lilly & Co.(LLY-N) 

December 12, 2013

One of the laggards in the pharma group.  If a company can’t do well in a good market, then it is time to move on.  Prefers JNJ-N for pharma exposure. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

One of the laggards in the pharma group.  If a company can’t do well in a good market, then it is time to move on.  Prefers JNJ-N for pharma exposure. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$49.230
Owned Owned
Unknown

DON'T BUY
Eli Lilly & Co.(LLY-N) 

November 27, 2013

Cheap on this year’s earnings, but not so cheap on next year’s. Part of the problem with this company is that one of their major drugs Cymbalta goes off patent at the end of 2013. In the 3rd quarter this drug was over 20% of their revenues, so they are looking at a pretty significant drop in revenues in 2014 and a more significant drop in earnings. A more interesting one would be Pfizer (PFE-N) as there are catalysts for change as they are looking at breaking this company up into 3 different divisions starting in 3 years but will start reporting on those divisions individually next year. He holds no pharmaceuticals at this time.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Cheap on this year’s earnings, but not so cheap on next year’s. Part of the problem with this company is that one of their major drugs Cymbalta goes off patent at the end of 2013. In the 3rd quarter this drug was over 20% of their revenues, so they are looking at a pretty significant drop in revenues in 2014 and a more significant drop in earnings. A more interesting one would be Pfizer (PFE-N) as there are catalysts for change as they are looking at breaking this company up into 3 different divisions starting in 3 years but will start reporting on those divisions individually next year. He holds no pharmaceuticals at this time.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Don Lato

President, Padlock Investment M...

Price Price
$50.360
Owned Owned
No

BUY
Eli Lilly & Co.(LLY-N) 

November 5, 2013

Been undergoing struggles with patent expiry and competition.  Massive R&D budget and it is hard to know when they will have the next block buster drug.  A good blue chip name to own.  JNJ might be a safer way to participate.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Been undergoing struggles with patent expiry and competition.  Massive R&D budget and it is hard to know when they will have the next block buster drug.  A good blue chip name to own.  JNJ might be a safer way to participate.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Colin Stewart

CEO & Port, JC Clark Investments...

Price Price
$50.370
Owned Owned
No

DON'T BUY
Eli Lilly & Co.(LLY-N) 

October 30, 2013

Has always traded at a lower valuation than some of the other pharmaceuticals. Has a fair number of patent expiry overhangs that it faces. There are only a few drugs that have been really able to keep their momentum going. On valuation, it always looks attractive, but with the problem of getting new drugs to market, there are other names that he would prefer such as Pfizer (PFE-N) or Johnson & Johnson (JNJ-N).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Has always traded at a lower valuation than some of the other pharmaceuticals. Has a fair number of patent expiry overhangs that it faces. There are only a few drugs that have been really able to keep their momentum going. On valuation, it always looks attractive, but with the problem of getting new drugs to market, there are other names that he would prefer such as Pfizer (PFE-N) or Johnson & Johnson (JNJ-N).

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Mohsin Bashir

VP Investm, Stone Asset Manageme...

Price Price
$49.210
Owned Owned
Unknown

BUY

50% payout ratio.  Drugs are coming off patent.  You are buying for yield and low volatility.  There are better names in the group but they are in the sweet spot in the market.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

50% payout ratio.  Drugs are coming off patent.  You are buying for yield and low volatility.  There are better names in the group but they are in the sweet spot in the market.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$54.560
Owned Owned
No

PARTIAL SELL
Eli Lilly & Co.(LLY-N) 

April 5, 2013

Had a very good run.  Due for a consolidation period.  If you are concerned, take half off the table. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

Had a very good run.  Due for a consolidation period.  If you are concerned, take half off the table. 

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Keith Richards

Portfolio , ValueTrend Wealth Ma...

Price Price
$56.480
Owned Owned
Unknown

BUY
Eli Lilly & Co.(LLY-N) 

March 6, 2012

All drug companies are facing the “patent cliff”. (Have a lot of drugs that are coming off patent.) This is pretty well known and all the stocks are cheap. 5% dividend yield. Dividend is safe and you have very good visibility into the cash flows.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
All drug companies are facing the “patent cliff”. (Have a lot of drugs that are coming off patent.) This is pretty well known and all the stocks are cheap. 5% dividend yield. Dividend is safe and you have very good visibility into the cash flows.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Burrows

President , Barometer Capital Ma...

Price Price
$38.640
Owned Owned
No

Showing 1 to 15 of 37 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days